Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Manchester, UK, January 4, 2024 – Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,862,337, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The […]
Our Head of Development, Sheryl Caswell is featured in the CCRA Yearbook discussing the impact of digital biomarkers on clinical research
Biomarkers have become increasingly important in the drug development process. But what is a biomarker and why are they useful to enable clinical trial design? Click here to download the PDF
A new era for schizophrenia drug development – Lessons for the future
Here we discuss challenges and opportunities highlighted by recent successes in drug development in schizophrenia, particularly the benefits of patient stratification to define patient subgroups most likely to respond to treatment.
Post-Covid-19 cognitive impairment: a new target for drug development?
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment.
Post-Covid-19 cognitive impairment: a new target for drug development?
Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne, and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. Click here to read the article online Alternatively, click here to download the PDF
Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
Monument Tx CSO to present positive data from first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, at AD/PD conference March 28th-April 1st 2023 Manchester, UK, March 27th, 2023: Monument Therapeutics, a stratified neuroscience company, today announced they will be presenting positive results from their lead clinical program at the AD/PD conference, March 28th–April […]
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, shows drug can access the brain San Francisco, USA, January 8, 2023: Monument Therapeutics, a stratified neuroscience company, will this week […]
Measuring functional outcomes in schizophrenia in an increasingly digital world
This review aims to give an overview of the different types of functional assessments commonly used in clinical trials and research involving patients with schizophrenia and highlight pertinent challenges surrounding the use of these as reliable, sensitive, and specific assessments in intervention trials.
Latent inhibition, aberrant salience, and schizotypy traits in cannabis users
Here we investigate the relative effects of cannabis use, schizotypy status, and self-reported aberrant salience experiences on salience processing, measured using a latent inhibition (LI) task (Granger et al., 2016), in a non-clinical population.
Disruption of overshadowing and latent inhibition in high schizotypy individuals
Here we investigated the relationship between selective attention and schizotypy, by comparing participants’ performance in two models: overshadowing and latent inhibition.
Enhanced latent inhibition in high schizotypy individuals
Here two within-participant experiments are reported that explore the relationship between schizotypy and latent inhibition without the confound of alternative learning phenomena.
Emotional bias training as a treatment for anxiety and depression: evidence from experimental medicine studies in healthy and medicated samples
Anxiety and depression are leading causes of disability worldwide, yet individuals are often unable to access appropriate treatment. There is a need to develop effective interventions that can be delivered remotely. Previous research has suggested that emotional processing biases are a potential target for intervention, and these may be altered through brief training programs.
Social cognitive dysfunction as a clinical marker: A systematic review of meta-analyses across 30 clinical conditions
We identified 31 meta-analyses that examined performance across relevant tasks among 30 different clinical populations. The results suggest that social cognitive deficits appear to be a core cognitive phenotype of many clinical conditions.
Using Affective Cognition to Enhance Precision Psychiatry
Major depressive disorder affects hundreds of millions of people, is among the leading causes of disability worldwide. While a range of effective drugs are available, the majority of patients do not achieve symptomatic remission. Precision psychiatry offers a range of exciting possibilities for optimizing effective prevention, diagnosis, and treatment of psychiatric disorders.
The Paired Associates Learning (PAL) Test: 30 Years of CANTAB Translational Neuroscience from Laboratory to Bedside in Dementia Research
The origins and rationale of the Cambridge Neuropsychological Test Automated Battery (CANTAB) as a cross-species translational instrument suitable for use in human neuropsychopharmacological studies are reviewed.
Assessing cognitive function in clinical trials of schizophrenia
Cognitive dysfunction in schizophrenia is an important target for novel therapies. Computerised cognitive assessment may optimise the statistical power of cognitive trials by reducing measurement error and between-site variability and decreasing patient attrition through increased tolerability.
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition
Here, two complementary experimental studies suggest latent inhibition is modified by manipulations that are relevant to the detection and treatment of schizophrenia. These results suggest that this latent inhibition task merits further investigation in the context of neurobiological sub-groups suitable for novel treatment strategies.
Postoperative cognitive dysfunction: an acute approach for the development of novel treatments for neuroinflammation
Here we discuss the use of postoperative cognitive decline (POCD), which is hypothesised to have a neuroinflammatory basis, as an acute indication to demonstrate the efficacy of novel neuroinflammatory drugs.
Latent inhibition and its potential as a biomarker for schizophrenia
Here we provide a brief review of the history behind latent inhibition and the limitations of existing human paradigms, before discussing a more recent latent inhibition task modification and its potential as a biomarker for schizophrenia.
The rise of digital biomarkers in neuroscience drug development
Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J. Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.
The rise of digital biomarkers in neuroscience drug development
Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J. Mark Treherne, Dr Jenny Barnett and Dr Paula Moran. Click here to download the article
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Stratified medicine company Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to treat […]
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation Monument Tx announce first-in-human study of MT1980, a novel treatment for neuroinflammation Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel […]
We are attending the BIO Conference: join us at two exciting sessions
We will be participating at the upcoming Biotechnology Innovation Organization conference taking place in San Diego, California, June 13-16. Members of our team will be speaking at two incredibly exciting sessions: Tackling Post-Covid Cognitive Impairment Wednesday, June 15th, 4:15pm – 5:15pm PDT https://www.bio.org/events/bio-international-convention/sessions/916081 Speaker: Dr Kiri Granger, Monument Tx, CSO Widespread evidence shows that cognitive problems are the […]
Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
Proud that our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (#POCD). As the article notes, estimates suggest that the overall incidence of POCD in older patients can be as high as 50-80% at discharge, 20-50% at six weeks and 10-30% at six months post-surgery. New therapies are […]
Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!
We are very proud that our fantastic CSO Dr Kiri Granger has been listed as one of In Vivo‘s 2022 ‘Rising Leaders’! The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care. Included for 2022 are investors, CEOs of small and mid-sized […]
Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA
Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA. Don’t miss her in-person talk: Using Digital Biomarkers to Apply a Stratified Approach to Neuroinflammation When: April 19th, 9AM EST Synopsis Applying digital biomarkers, in combination with standard inflammatory markers, to aid identification of people at high […]
Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference
Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference Monument Tx CSO to present preclinical data for lipid reformulation of anti-inflammatory compound MT1980 at AD/PD conference in Barcelona 15-20th March 2022 Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be […]
Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference
Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference Monument Tx CSO to present novel biomarker predicting risk for developing POCD at AD/PD conference in Barcelona 15-20th March 2022 Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will […]
Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic Lipid reformulation of anti-inflammatory compound MT1980 for POCD accelerating into clinic in 2022 Manchester, UK, Dec 14, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised an additional £0.5 million to accelerate the development of its anti- neuroinflammation compound MT1980, […]
Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study
Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study Aim to bring novel digital biomarker-drug combination that overcomes biological heterogeneity challenge to clinic by 2022 Manchester, UK, September 20, 2021: Monument Therapeutics, a stratified medicine company, today announced a pioneering preclinical study to support the use of their proprietary non-invasive biomarker for […]
New Interview in Scrip
New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers. Read the interview here. For further information, contact: Jenny Barnett, CEO E: jbarnett@monumenttx.com Media: Richard Hayhurst/Janet Joy E: Richard@rhapr.eu or jan@rhapr.eu Tel: +44 7711 821527 Notes to Editors: […]
Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board
Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board. Paula brings deep expertise in psychopharmacology, using animal and human translational models to understand the biology of schizophrenia and Alzheimer’s disease. Following on from her PhD at the University of Ireland, Paula spent 6 years as a Scientist […]
Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director Julian brings deep expertise in the development and commercialising of repurposed and reprofiled compounds. He was co-founder and CEO of Acacia Pharma Group plc, a hospital pharmaceuticals company which launched its lead product BARHEMSYS®, a repurposed […]
Digital brain biomarker company Monument Therapeutics raises £2.6 million
Cambridge Cognition spin-out targets schizophrenia and post-operative cognitive dysfunction Manchester, UK, July 1st, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug […]
Latent inhibition and its potential as a biomarker for schizophrenia
Aliquam sit amet ipsum eu tellus tincidunt commodo. Aenean metus tellus, vehicula at nisl vel, laoreet gravida risus. Integer nec fringilla neque. Vivamus tincidunt dui vitae augue.
Richard Bungay Joins the Board as a Director
Change of Director – 22nd April 2021 Monument Therapeutics is pleased to announce that Richard Bungay will join the Board as a Director with immediate effect. Mr. Bungay has over 25 years’ experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with […]
Postoperative cognitive dysfunction: an acute approach for the development of novel treatments for neuroinflammation
Aliquam sit amet ipsum eu tellus tincidunt commodo. Aenean metus tellus, vehicula at nisl vel, laoreet gravida risus. Integer nec fringilla neque. Vivamus tincidunt dui vitae augue.
